JP2012515225A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515225A5
JP2012515225A5 JP2011546409A JP2011546409A JP2012515225A5 JP 2012515225 A5 JP2012515225 A5 JP 2012515225A5 JP 2011546409 A JP2011546409 A JP 2011546409A JP 2011546409 A JP2011546409 A JP 2011546409A JP 2012515225 A5 JP2012515225 A5 JP 2012515225A5
Authority
JP
Japan
Prior art keywords
benzo
optionally substituted
pyridazin
triazole
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011546409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515225A (ja
JP5858789B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/021275 external-priority patent/WO2010083465A1/en
Publication of JP2012515225A publication Critical patent/JP2012515225A/ja
Publication of JP2012515225A5 publication Critical patent/JP2012515225A5/ja
Application granted granted Critical
Publication of JP5858789B2 publication Critical patent/JP5858789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011546409A 2009-01-16 2010-01-15 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬 Active JP5858789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14544809P 2009-01-16 2009-01-16
US61/145,448 2009-01-16
PCT/US2010/021275 WO2010083465A1 (en) 2009-01-16 2010-01-15 Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014208912A Division JP2015007135A (ja) 2009-01-16 2014-10-10 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬

Publications (3)

Publication Number Publication Date
JP2012515225A JP2012515225A (ja) 2012-07-05
JP2012515225A5 true JP2012515225A5 (OSRAM) 2013-02-28
JP5858789B2 JP5858789B2 (ja) 2016-02-10

Family

ID=41683427

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011546409A Active JP5858789B2 (ja) 2009-01-16 2010-01-15 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬
JP2014208912A Pending JP2015007135A (ja) 2009-01-16 2014-10-10 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014208912A Pending JP2015007135A (ja) 2009-01-16 2014-10-10 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬

Country Status (13)

Country Link
US (5) US8546433B2 (OSRAM)
EP (1) EP2387395B1 (OSRAM)
JP (2) JP5858789B2 (OSRAM)
CN (1) CN102281875B (OSRAM)
AU (1) AU2010204578B2 (OSRAM)
BR (1) BRPI1007046B1 (OSRAM)
CA (1) CA2749843C (OSRAM)
ES (1) ES2528032T3 (OSRAM)
PL (1) PL2387395T3 (OSRAM)
PT (1) PT2387395E (OSRAM)
RU (1) RU2555326C2 (OSRAM)
SG (1) SG172997A1 (OSRAM)
WO (1) WO2010083465A1 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884119B2 (en) * 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
EP2079736B1 (en) 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
CA2710230C (en) 2006-12-29 2016-02-23 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008083367A2 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5567837B2 (ja) 2006-12-29 2014-08-06 ライジェル ファーマシューティカルズ, インコーポレイテッド Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール
WO2009054864A1 (en) * 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5711537B2 (ja) 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ピリミジン−2−アミン化合物およびjakキナーゼの阻害剤としてのその使用
WO2010005879A1 (en) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環式ヘテロアリール置換トリアゾール
JP4644273B2 (ja) * 2008-07-15 2011-03-02 本田技研工業株式会社 車両周辺監視装置
CN102281875B (zh) * 2009-01-16 2017-09-22 里格尔药品股份有限公司 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
ES2535176T3 (es) 2009-09-28 2015-05-06 Qilu Pharmaceutical Co., Ltd Derivados de 4-(anilino sustituido)quinazolina como inhibidores de la tirosina quinasa
GB201207722D0 (en) 2012-05-02 2012-06-13 Bergenbio As Method
US20150164800A1 (en) 2012-07-25 2015-06-18 Xetrios Therapeutics, Inc. Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
EP3074390B1 (en) 2013-11-27 2020-07-08 SignalChem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
WO2015082887A2 (en) * 2013-12-02 2015-06-11 Bergenbio As Use of kinase inhibitors
US20170027940A1 (en) * 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US10028958B2 (en) * 2014-04-19 2018-07-24 Massachusetts Institute Of Technology Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors
GB201420285D0 (en) 2014-11-14 2014-12-31 Bergenbio As Process
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
CN106083764B (zh) * 2016-07-11 2018-09-18 上海皓元生物医药科技有限公司 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
US20200289613A1 (en) * 2017-11-04 2020-09-17 Aravive Biologics, Inc. Methods of treating metastatic cancers using axl decoy receptors
US12097194B2 (en) 2018-09-18 2024-09-24 Signalchem Lifesciences Corporation Combination therapy for treating blood cancer
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
JPWO2022220227A1 (OSRAM) * 2021-04-14 2022-10-20
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1403866A (en) 1971-12-06 1975-08-28 Wyeth John & Brother Ltd Derivatives of 3-amino-1,2,4-triazoles
US4512992A (en) 1980-06-13 1985-04-23 Burroughs Wellcome Co. Treatment with dialkoxy pyridopyrimidine compounds
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US6258360B1 (en) 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
GB9918180D0 (en) 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
DE60120494T2 (de) 2000-12-22 2006-12-21 Ortho-Mcneil Pharmaceutical, Inc. Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
EP1487436A4 (en) 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
AU2003222310B2 (en) 2002-05-03 2009-04-09 Janssen Pharmaceutica N.V. Polymeric microemulsions
ES2378987T3 (es) 2002-08-06 2012-04-19 Toray Industries, Inc. Remedio o agente preventivo para una enfermedad renal y procedimiento para diagnosticar una enfermedad renal
WO2004039955A2 (en) 2002-10-29 2004-05-13 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
JP2006520397A (ja) 2003-03-14 2006-09-07 アストラゼネカ アクチボラグ 新規融合トリアゾロン類及びその使用
CA2526387A1 (en) 2003-06-12 2004-12-23 Astellas Pharma Inc. Benzamide derivative or salt thereof
TW200514776A (en) 2003-08-06 2005-05-01 Vertex Pharma Aminotriazole compounds useful as inhibitors of protein kinases
CA2554925A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
AU2005212218A1 (en) 2004-02-11 2005-08-25 Janssen Pharmaceutica, N.V. Process for the preparation of substituted triazole compounds
EP1763514A2 (en) 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
AU2005272815A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of ATP-utilizing enzymes
DK1791830T3 (da) 2004-09-17 2011-04-18 Vertex Pharma Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
DE602005024293D1 (de) 2004-10-21 2010-12-02 Vertex Pharma Triazole als hemmer von proteinkinasen
US20060166936A1 (en) 2004-10-29 2006-07-27 Hayley Binch Diaminotriazole compounds useful as inhibitors of protein kinases
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US7884119B2 (en) 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
US8217037B2 (en) 2006-04-07 2012-07-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
FR2908131B1 (fr) 2006-11-03 2009-01-09 Univ Haute Alsace Etablissemen Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique
JP2008130120A (ja) 2006-11-17 2008-06-05 Sharp Corp 光ピックアップ装置
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
JP5567837B2 (ja) 2006-12-29 2014-08-06 ライジェル ファーマシューティカルズ, インコーポレイテッド Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール
WO2008083367A2 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2079736B1 (en) 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710230C (en) 2006-12-29 2016-02-23 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CN101707863A (zh) 2007-06-15 2010-05-12 Irm责任有限公司 蛋白激酶抑制剂及其使用方法
WO2009054864A1 (en) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5711537B2 (ja) 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ピリミジン−2−アミン化合物およびjakキナーゼの阻害剤としてのその使用
WO2010005879A1 (en) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環式ヘテロアリール置換トリアゾール
CN102281875B (zh) 2009-01-16 2017-09-22 里格尔药品股份有限公司 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法

Similar Documents

Publication Publication Date Title
JP2012515225A5 (OSRAM)
RU2011132118A (ru) Ингибиторы axl для применения в комбинированной терапии для предотвращения, устранения или лечения метастизирующего рака
JP2020105211A5 (OSRAM)
JP7174735B2 (ja) (s)-3-(4-((4-(モルホリノメチル)ベンジル)オキシ)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法
US10968235B2 (en) N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
EP3468972B1 (en) Compounds and compositions for inhibiting the activity of shp2
EP3310771B1 (en) Compounds and compositions for inhibiting the activity of shp2
AU2018358157B2 (en) Modulators of the integrated stress pathway
EP3094627B1 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
EP3310774B1 (en) Compounds and compositions for inhibiting the activity of shp2
EP3724178B1 (en) 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
CN105407889B (zh) 针对Rb阳性异常细胞增殖的HSPC节制性治疗
JP2017515802A5 (OSRAM)
JP2022141811A5 (OSRAM)
JP2016539138A5 (OSRAM)
CA2943022C (en) Benzo[g]pyrido[2,1-b] quinazoline carboxamide compounds which inhibit rna polymerase, compositions including such compounds, and their use
KR20210088584A (ko) 소분자 cd-47 저해제와 다른 항암제의 조합물
CA3056308A1 (en) Pharmaceutical compounds
CN110402141A (zh) Axl抑制剂和EGFR酪氨酸激酶抑制剂的联合疗法
JPWO2020257429A5 (OSRAM)
JP2022512874A (ja) 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用
CN111989092A (zh) Bet抑制剂和蛋白酶体抑制剂的联合治疗
JP2020528418A (ja) BET阻害剤及びBcl−2阻害剤を用いた併用療法
JPWO2021263205A5 (OSRAM)
HK40038452B (en) 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer